Market Place
Sourcing Support
Aptamer Group Inks New Development Deals, Licensing Agreement
15 May 2025 //
CONTRACTPHARMA
Nucleic Acid Aptamer Pharmacokinetics Extended in Joint Research
06 May 2025 //
PR NEWSWIRE
HKBU Aptamer for X-link Hypophosphatemia Receive Orphan Designation
23 Dec 2024 //
PR NEWSWIRE
Top pharma experts to evaluate Optimer for precision liver medicines
22 Apr 2024 //
BIOSPECTRUM ASIA
Aptamer Group & BaseCure Therapeutics join hands for new targeted gene therapies
02 Feb 2023 //
EXPRESS PHARMA
BaseCure collaborates with Aptamer Group to boost gene therapies
01 Feb 2023 //
PHARMATIMES
Aptamer Group Appointment of Interim Chief Commercial Officer
10 Jan 2023 //
GLOBENEWSWIRE
Aptamer Group Opens New State-of-the-Art Facilities
28 Nov 2022 //
CONTRACTPHARMA
Aptamer Group signs deal with Flip Gene to support inducible gene therapies
16 Jun 2022 //
MANUFACTURINGCHEMIST
Aptar CSP’s Activ-Blister Solutions Available for Manufacturing in Europe
23 May 2022 //
CONTRACTPHARMA
Aptamer Group and PinotBio Extend Collaboration Agreement
23 May 2022 //
CONTRACTPHARMA
Aptamer Group trades on AIM market of the London Stock Exchange
21 Dec 2021 //
YORKPRESS
UK biotech firm Aptamer to float valued at £80.7m
18 Dec 2021 //
THEGUARDIAN
Aptamer, Bio-Works partner for co-development & gene therapy manufacturing
27 Aug 2021 //
PHARMABIZ
Aptamer Group and Bio-Works Technologies Enter Agreement
25 Aug 2021 //
CONTRACTPHARMA
Aptamer and WuXi AppTec Form Research Partnership
22 Jul 2021 //
CONTRACT PHARMA
Aptamer partners with five global pharma companies to develop Optimers
14 Jul 2021 //
PHARMABIZ
Aptamer partners with five global pharma companies to develop Optimers
14 Jul 2021 //
PHARMABIZ
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.